You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Patient and caregiver resources for sAML and treatment with VYXEOS

It’s important to feel supported every step of the way while receiving secondary acute myeloid leukemia (sAML) treatment. The resources below may help answer questions you may have about treatment, financial reimbursement, and support groups for those in the AML community.

Notes icon

Frequently asked questions (FAQs)

Explore our most frequently asked questions and learn more about VYXEOS (vix-e-ose).
Get answers.

Notes icon

Resource library

We’re here for you. Download educational information and find support groups.
Find sAML support and resources.

Money icon

sAML patient support

Learn about financial reimbursement options with JazzCares.
Financial options.


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.